• Animal Retroviral Infections Suggest Third Kind of Potential Treatment: HIV Harm Reduction
  Besides antivirals and immune-based treatments, a third approach is to reduce the harm caused indirectly by HIV, which is probably more important than the direct killing of infected cells. Some animals do not get sick when infected with HIV-like viruses despite very high viral loads -- suggesting that they have successfully evolved to tolerate the virus instead of eradicating or suppressing it. Understanding how they do so might lead to a new kind of HIV treatment.

• T-20 (Fuzeon) Gets Priority Review
  The FDA plans to decide on T-20 approval within six months.

• ICAAC Clinical Trials Review Available
  You can read a quick summary of the HIV clinical trial results presented at a scientific conference on anti-infection drugs.

• Hepatitis C: FDA Public Meeting on Peginterferon Plus Ribavirin, Nov. 14
  An FDA advisory committee will hold a public meeting on a new treatment for hepatitis C.

• Anti-HIV Factor Discovered
  Scientists at the Aaron Diamond AIDS Research Center believe they have discovered a major component of a long-sought soluble anti-HIV factor produced by certain CD8 cells.

• Retroviruses Scholarship, Community Press, Other Deadlines Soon
  Scientific abstracts are due October 23, and important community deadlines begin November 1 for international travelers, November 8 for U.S. community press and scholarship applicants.

• Treat-Your-Workers.org; International Coca-Cola Protest October 17
  ACT UP and others demand better medical coverage for African workers with HIV.

• Chinese AIDS Activist Released
  Dr. Wan Yan Hai was released September 20.

• Nonoxynol-9 Dangers: Health Experts Warn Against Rectal Use
  Dozens of experts and organizations call for stopping all rectal use of N-9.

ISSN # 1052-4207

Copyright 2002 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.